TP53 and lymphoma: In our study, p53 expression levels correlated with PFS and OS, and highlighted the potential clinical effectiveness of using bendamustine in combination with rituximab (BR) [19], which will be evaluated in the treatment of lymphoma with higher p53 expression levels in the near future.